NCT07455058

Water Vapor Ablation for Prostate Cancer: Long-Term Registry

Vanquish® Water Vapor Ablation for PrOstate CanceR: Long-Term Registry

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2,500 (estimated)
• Sponsor: Francis Medical Inc. · Industry
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DEVICE	Vanquish Therapy	The Francis Medical, Inc. Vanquish Water Vapor Ablation Device ("Vanquish" or "Vanquish System") is a transurethral thermal water vapor ablation device. The Vanquish System is designed ablate prostate tissue, while minimizing side effects.

Timeline

• Start date: 2026-04-30
• Primary completion: 2041-04-30
• Completion: 2041-07-31
• First posted: 2026-03-06
• Last updated: 2026-03-06

Regulatory

• FDA-regulated device study